Gordonville

Researchers are evaluating the safety, tolerability, and effectiveness of MZE782 tablets in adults aged 18 to 75 years who have Phenylketonuria PKU, a genetic condition affecting amino acid metabolism. This Phase 2 study aims to assess how well MZE782 works and how safe it is for people with PKU by comparing different doses of the drug to a placebo. The study is sponsored by Maze Therapeutics and uses a randomized, parallel design with multiple groups. Participants will receive either a low or high dose of MZE782 or a matching placebo tablet. The treatment period lasts up to 17 weeks, during which plasma phenylalanine Phe levels and drug concentrations will be regularly measured. Some study groups may have specific requirements regarding blood Phe levels or background treatments, including stopping certain PKU medications before starting the study drug. The study includes multiple cohorts receiving different doses or placebo, with evaluations at baseline and multiple weeks throughout treatment. During the trial, participants will have regular blood tests to measure Phe levels and monitor drug levels at several time points up to week 13. Researchers will track safety by recording any adverse events from the start through week 17. Participants must maintain a consistent diet and protein intake during the study. The total participation lasts several months, with close monitoring to assess both the impact of MZE782 on PKU and its safety profile.

Researchers are studying the natural progression and variations of muscle disease caused by genetic changes in the TNNT1 gene, specifically focusing on autosomal recessive TNNT1-associated myopathy, including infantile-onset and childhood-onset forms of nemaline rod myopathy. The study aims to define important outcome measures to support future clinical trials of new treatments. This observational study welcomes children and adults worldwide and includes both prospective and cross-sectional groups. Participants in the prospective group join soon after diagnosis during early infancy and are followed over time with repeated assessments until they reach key study outcomes. Those in the cross-sectional group provide their information once at any time after diagnosis. Assessments include vital signs, physical exams, growth and motor milestone documentation, blood tests, heart ultrasounds echocardiograms, and chest X-rays. These evaluations happen at participants homes, the Clinic for Special Children, or partnering clinical sites, depending on individual circumstances. During the study, participants undergo regular monitoring of their health and development. The research team collects detailed medical history, physical findings, and growth measurements. The main outcome measured is event-free survival over up to 15 years, with secondary outcomes including motor milestones and overall thriving. The studys duration spans several years, allowing long-term observation of disease progression under current treatments.